Orlistat, a new lipase inhibitor for the management of obesity

Pharmacotherapy

Volumn 20, Issue 3, 2000, Pages 270-279

  Heck, Amy M ^a,d   Yanovski, Jack A ^b   Calis, Karim Anton ^c  

^a PURDUE UNIVERSITY   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ATENOLOL; CAPTOPRIL; DIGOXIN; FUROSEMIDE; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PRAVASTATIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; VITAMIN; WARFARIN;

BREAST CANCER; CANCER RISK; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; STRUCTURE ACTIVITY RELATION; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

EID: 0034048643     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.4.270.34882     Document Type: Review

References (49)

1. Kuczmarski RJ, Carroll MD, Flegal KM, et al. Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988-1994). Obes Res 1997;5:542-8.
2. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes 1998;22:39-47.
3. McGinnis JM, Forge WH. Actual causes of death in the United States. JAMA 1993;270:2207-12.
4. Rosenbaum M, Leibel R, Hirsch J. Obesity. N Engl J Med 1997;337:6396-407.
5. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119:655-60.
6. Wolf AM, Colditz GA. Current estimates of the economic costs of obesity in the United States. Obes Res 1998;6:97-106.
7. U.S. Department of Health and Human Services. National Heart Lung and Blood Institute obesity initiative expert panel on the identification, evaluation, and treatment of overweight and obesity in adults. Washington, DC: U.S. Public Health Service, 1998.
8. Leonhardt M, Hrupka B, Langhans W, et al. New approaches in the pharmacological treatment of obesity. Eur J Nutr 1999;38(1):1-13.
9. Roche Pharmaceuticals. Xenical (orlistat) product information. Nutley, NJ;May 1999.
10. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988;256:357-61.
11. Borgstrom B. Mode of action of tetrahydrolipstatin, a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988:962:308-16.
12. Hadvary P, Sidler W, Meister W, et al. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J Biol Chem 1991;266(4):2021-7.
13. Ransac S, Gargouri Y, Moreau H, et al. Inactivation of pancreatic and gastric lipases by tetrahydrolipstatin and alkyl-dithio-5-(2-nitrobenzoic acid). Eur J Biochem 1991;202: 395-400.
14. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995;35:1103-8.
15. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996:36:1006-11.
16. Bennett P, Li Y, Edom R, et al. Quantitative determination of orlistat (tetrahydrolipostatin, Ro 18-0647) in human plasma by high-performance liquid chromatography couple with ion spray tandem mass spectrometry. J Mass Spectrom 1997;32;739-49.
17. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999;39:41-6.
18. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipostatin). Am J Clin Nutr 1992;55:309S-13.
19. Reitsma JB, Cabezas MC, de Bruin TWA, et al. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipostatin, a pancreatic lipase inhibitor. Metabolism 1994;43(3):293-8.
20. Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994;46:405-10.
21. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995;19:221-6.
22. James WPT, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes 1997;21(suppl 3):S24-30.
23. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998;54:125-32.
24. Drent ML, Van Der Veen EA. First clinical studies with orlistat: a short review. Obes Res 1995;3:623S-5.
25. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998;16:2013-17.
26. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235-42.
27. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-73.
28. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397-415.
29. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21(8):1288-94.
30. United Kingdom Prospective Diabetes Study Group. Relative efficacy of randomly allocated diet, suphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83-8.
31. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhihitor, for weight maintenance after conventional dieting; a 1-year study Am J Clin Nutr 1999;69:1108-16.
32. Hartmann D, Guzelhan C, Zuiderwijk PB, Odink J. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996;50:421-4.
33. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996;36:654-8.
34. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996;36:352-5.
35. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokmetics of digoxin in healthy volunteers. J Clin Pharmacol 1995;35:840-3.
36. Weber C, Tam YK, Schmidtke-Schrezenmeier G, Jonkmann JH, Van Brummelen P. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different anti-hypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996;51:87-90.
37. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996;36:659-66.
38. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995;35: 521-5.
39. Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistal with ethanol in health volunteers. Eur J Clin Pharmacol 1998;54:773-7.
40. McNeely W, Benfield P. Orlistat. Drugs 1998;56(2):241-9.
41. Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci. 1996;41:2404-8.
42. Halsted CH. Is blockade of pancreatic lipase the answer? [editorial]. Am J Clin Nutr 1999;69:1059-60.
43. McCarthy WJ. Orlistat and weight loss [letter]. Lancet 1998;352:1473.
44. Lekkerkerker JFF, Diemont WL, Koopmans PP. Orlistat and weight loss [letter]. Lancet 1998;352:1474.
45. Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996;36:152-9.
46. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996;36:647-53.
47. U.S. Food and Drug Administration. Endocrinologie and Metabolic Drugs Advisory Committee. Verbatim transcript of a meeting March 13, 1998, NDA 20-766: orlistat (tetrahydrolipstatin).
48. Roche Pharmaceuticals. Data on file. Nutley, NJ;August 1999.
49. Cardinale V, ed. Drug topics redbook update. Montvale, NJ: Medical Economics Co., 1999.